FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2989723240> ?p ?o ?g. }

• W2989723240 abstract "Abstract Spinocerebellar ataxia type 3 (SCA3) is a devastating multisystemic neurodegenerative disease for which targeted molecular therapies are coming into reach (e.g. antisense oligonucleotides). To pave the way for upcoming translational trials, easily accessible biomarkers in SCA3 are needed, particularly for subjects at the preataxic stage and cross-validated also in animal models. We hypothesised that serum neurofilaments might serve as blood biomarkers of disease progression in both human SCA3 and mouse models, expecting increased concentrations already at the preataxic stage. Serum neurofilament light (NfL) and phosphorylated neurofilament heavy (pNfH) levels were determined by ultra-sensitive single molecule array (Simoa) in cross-sectional samples of ataxic and preataxic SCA3 subjects and controls in two independent cohorts (ESMI cohort = cohort #1: n=160, EuroSCA/RiSCA cohort = cohort #2: n=89). Serum NfL and pNfH were also assessed in a 304Q SCA3 knock-in mouse model across presymptomatic and symptomatic disease stages (n=147). Ataxic SCA3 subjects showed increased serum NfL (p<0.001) and pNfH (p<0.001) levels in cohort #1, with NfL levels already increased in preataxic subjects (p<0.001). All these results were replicated in cohort #2 (all p<0.001). Cross-sectional NfL levels correlated with clinical disease severity (Scale for the Assessment and Rating of Ataxia [SARA]; r=0.43, p<0.001) and with longitudinal disease progression (annual SARA score change, ϱ=0.42, p=0.012). CAG count and age were significant predictors of individual NfL concentrations (each p<0.001). NfL levels in preataxic subjects increased with proximity to individual expected onset of ataxia (p<0.001), with significant elevations already 7.5 years before onset. Serum NfL and pNfH increases in SCA3 subjects were paralleled by similar changes in SCA3 knock-in mice, here also already starting at the presymptomatic stage and close to the onset of ataxin-3 protein increase. Serum concentrations of neurofilaments, particularly NfL, might provide easily accessible biomarkers of disease severity in both ataxic and preataxic SCA3 subjects and mice prior to conversion. Neurofilaments thus entail potential applications as progression, onset/proximity and treatment-response markers in both human and murine SCA3 trials." @default.
• W2989723240 created "2019-12-05" @default.
• W2989723240 creator A5003938743 @default.
• W2989723240 creator A5004841118 @default.
• W2989723240 creator A5004903531 @default.
• W2989723240 creator A5008310181 @default.
• W2989723240 creator A5017611404 @default.
• W2989723240 creator A5021476913 @default.
• W2989723240 creator A5022217754 @default.
• W2989723240 creator A5022886141 @default.
• W2989723240 creator A5027293126 @default.
• W2989723240 creator A5028419680 @default.
• W2989723240 creator A5028895894 @default.
• W2989723240 creator A5037136657 @default.
• W2989723240 creator A5037328125 @default.
• W2989723240 creator A5041018987 @default.
• W2989723240 creator A5043265622 @default.
• W2989723240 creator A5043517773 @default.
• W2989723240 creator A5047692078 @default.
• W2989723240 creator A5047819566 @default.
• W2989723240 creator A5057192241 @default.
• W2989723240 creator A5059290458 @default.
• W2989723240 creator A5062512325 @default.
• W2989723240 creator A5063315866 @default.
• W2989723240 creator A5067483880 @default.
• W2989723240 creator A5069442374 @default.
• W2989723240 creator A5070361492 @default.
• W2989723240 creator A5075596279 @default.
• W2989723240 creator A5079598236 @default.
• W2989723240 creator A5083503412 @default.
• W2989723240 creator A5087821155 @default.
• W2989723240 creator A5088519121 @default.
• W2989723240 date "2019-11-27" @default.
• W2989723240 modified "2023-10-16" @default.
• W2989723240 title "Neurofilaments as blood biomarkers at the preataxic and ataxic stage of spinocerebellar ataxia type 3: a cross-species analysis in humans and mice" @default.
• W2989723240 cites W1480524493 @default.
• W2989723240 cites W1519439387 @default.
• W2989723240 cites W1820977370 @default.
• W2989723240 cites W1986865371 @default.
• W2989723240 cites W2001683794 @default.
• W2989723240 cites W2056196309 @default.
• W2989723240 cites W2064863604 @default.
• W2989723240 cites W2117257456 @default.
• W2989723240 cites W2120527029 @default.
• W2989723240 cites W2121745049 @default.
• W2989723240 cites W2131270962 @default.
• W2989723240 cites W2306559597 @default.
• W2989723240 cites W2342233016 @default.
• W2989723240 cites W2404198556 @default.
• W2989723240 cites W2593438550 @default.
• W2989723240 cites W2614808368 @default.
• W2989723240 cites W2623948558 @default.
• W2989723240 cites W2626182344 @default.
• W2989723240 cites W2747198643 @default.
• W2989723240 cites W2793743434 @default.
• W2989723240 cites W2801410091 @default.
• W2989723240 cites W2808202810 @default.
• W2989723240 cites W2889223700 @default.
• W2989723240 cites W2900512212 @default.
• W2989723240 cites W2909595713 @default.
• W2989723240 cites W2910313823 @default.
• W2989723240 cites W2954934155 @default.
• W2989723240 cites W2986279507 @default.
• W2989723240 cites W2987784868 @default.
• W2989723240 doi "https://doi.org/10.1101/19011882" @default.
• W2989723240 hasPublicationYear "2019" @default.
• W2989723240 type Work @default.
• W2989723240 sameAs 2989723240 @default.
• W2989723240 citedByCount "0" @default.
• W2989723240 crossrefType "posted-content" @default.
• W2989723240 hasAuthorship W2989723240A5003938743 @default.
• W2989723240 hasAuthorship W2989723240A5004841118 @default.
• W2989723240 hasAuthorship W2989723240A5004903531 @default.
• W2989723240 hasAuthorship W2989723240A5008310181 @default.
• W2989723240 hasAuthorship W2989723240A5017611404 @default.
• W2989723240 hasAuthorship W2989723240A5021476913 @default.
• W2989723240 hasAuthorship W2989723240A5022217754 @default.
• W2989723240 hasAuthorship W2989723240A5022886141 @default.
• W2989723240 hasAuthorship W2989723240A5027293126 @default.
• W2989723240 hasAuthorship W2989723240A5028419680 @default.
• W2989723240 hasAuthorship W2989723240A5028895894 @default.
• W2989723240 hasAuthorship W2989723240A5037136657 @default.
• W2989723240 hasAuthorship W2989723240A5037328125 @default.
• W2989723240 hasAuthorship W2989723240A5041018987 @default.
• W2989723240 hasAuthorship W2989723240A5043265622 @default.
• W2989723240 hasAuthorship W2989723240A5043517773 @default.
• W2989723240 hasAuthorship W2989723240A5047692078 @default.
• W2989723240 hasAuthorship W2989723240A5047819566 @default.
• W2989723240 hasAuthorship W2989723240A5057192241 @default.
• W2989723240 hasAuthorship W2989723240A5059290458 @default.
• W2989723240 hasAuthorship W2989723240A5062512325 @default.
• W2989723240 hasAuthorship W2989723240A5063315866 @default.
• W2989723240 hasAuthorship W2989723240A5067483880 @default.
• W2989723240 hasAuthorship W2989723240A5069442374 @default.
• W2989723240 hasAuthorship W2989723240A5070361492 @default.
• W2989723240 hasAuthorship W2989723240A5075596279 @default.
• W2989723240 hasAuthorship W2989723240A5079598236 @default.
• W2989723240 hasAuthorship W2989723240A5083503412 @default.
• W2989723240 hasAuthorship W2989723240A5087821155 @default.
• W2989723240 hasAuthorship W2989723240A5088519121 @default.

• next